[ 英語タイトル ] Cutaneous T-cell Lymphoma Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0084155

Survey : Mordor Intelligence

Publish On : November, 2020

Number of Pages : 114

Category : Healthcare and Pharmaceuticals

Study Area : Global

Report format : PDF

Sales price option (consumption tax not included)

[Report Description]

Certain factors that are driving the market growth include rise in lymphoma cancer incidence and growing geriatric population.

Cutaneous T-cell lymphomas (CTCL) are the most common types of skin lymphoma. More than 3 out of every 4 skin lymphomas diagnosed are CTCLs. The two most common types of CTCL are mycosis fungoides (MF), which is slow-growing in the early stages, and Sézary Syndrome (SS), which is a more aggressive form of CTCL. According to Cutaneous Lymphoma Foundation, CTCL is a rare family of diseases, with approximately 3,000 new cases reported in the United States every year and about 16,000 – 20,000 Americans have mycosis fungoides. CTCL is more common in patients older than 50 years of age compared to younger people and it develops more often in men than in women, with the highest incidence rates being reported amongst African-Americans.

Key Market Trends

Mycosis Fungoides Segment is Expected to Register a Significant Growth in the Forecast Years

By type, the market has been segmented into Mycosis Fungoides (MF), Sezary Syndrome (SS) and others. Mycosis Fungoides is the most frequent type of cutaneous T-cell lymphoma which usually involves the skin and grows slowly over many years. It is very difficult to diagnose, especially in the early stages. MF is more common in men compared to women, in blacks compared to whites, and in older population compared to younger people. In addition, sezary syndrome is considered to be the second most common type of CTCL and characterized by the presence of lymphoma cells in the blood.

North America dominates the Cutaneous T- cell Lymphoma Market

North America dominates the market owing to the upsurge in the demand for progressive treatment options and early adoption of new technologies. Cutaneous T-cell Lymphoma (CTCL) is the rare form of T-cell lymphoma. There are about 3,000 new cases of CTCL in the U.S. each year. Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool, emerging economies, and a rise in the collaboration of domestic and international companies in these regions, thus driving this market.

Competitive Landscape

The market studied is moderately competitive and consists of several major players. Some of the key players in the cutaneous T-cell lymphoma market includes Bausch Health Companies Inc., Celgene Corporation, Helsinn Healthcare SA, Kyowa Hakko Kirin Co., Ltd., Merck & Co. Inc., Seattle Genetics, and Soligenix, Inc., which are having presence internationally and provide these products across the globe.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support